This study uses a novel approach to gene therapy in which plasmid DNA is targeted to the pancreas in vivo using ultrasound-targeted microbubble destruction (UTMD) to achieve islet regeneration. Intravenous microbubbles carrying plasmids are destroyed within the pancreatic microcirculation by ultrasound, achieving local gene expression that is further targeted to b-cells by a modified rat insulin promoter (RIP3.1). A series of genes implicated in endocrine development were delivered to rats 2 days after streptozotocin-induced diabetes. The genes, PAX4, Nkx2.2, Nkx6.1, Ngn3 and Mafa, produced a-cell hyperplasia, but no significant improvement in b-cell mass or blood glucose level 30 days after UTMD. In contrast, RIP3.1-NeuroD1 promoted islet regeneration from surviving b-cells, with normalization of glucose, insulin and C-peptide levels at 30 days. In a longer-term experiment, four of six rats had a return of diabetes at 90 days, accompanied by b-cell apoptosis on Tunel staining. Pretreatment with the JNK inhibitor SP600125 successfully blocked b-cell apoptosis and resulted in restoration of b-cell mass and normalization of blood glucose level for up to 90 days. This technique allows in vivo islet regeneration, restoration of b-cell mass and normalization of blood sugar, insulin and C-peptide in rats without viruses.
Introduction
Control of blood glucose is often inadequate in diabetes, as drug therapy, including insulin replacement, is unable to replicate the glucose regulatory function of normal islets. Accordingly, new treatment strategies have focused on replenishing the deficiency of b-cell mass that is common to both major forms of diabetes by islet transplantation or b-cell regeneration.
1,2 Islet transplantation has been limited by the supply of donor islets and by the need for immunosuppressive therapy. 3 Islet regeneration has been successful in animal models, primarily targeting liver tissue using viral vectors [4] [5] [6] [7] that are unlikely to be used in humans for safety reasons. A novel approach to gene therapy is to target the delivery of DNA to pancreatic islets using ultrasound-targeted microbubble destruction (UTMD). 8, 9 Intravenous microbubbles carrying plasmid DNA are destroyed within the pancreatic microcirculation by ultrasound, achieving local gene expression that can be further targeted to b-cells using a modified rat insulin-I promoter. UTMD has been used to deliver betacellulin and PDX1 in rats with streptozotocin (STZ)-induced diabetes, with reversal of diabetes for up to 15 days by reprogramming pancreatic acinar cells into insulin-producing cells. 10 Similarly, direct injection of adenoviri encoding a combination of genes PDX1, neurogenin3 and Mafa into mouse pancreata has been shown to reprogram exocrine cells into small insulin-producing cells without formation of islets. 11 However, regeneration of islets within the pancreas has remained an elusive goal of gene therapy. This study sought to evaluate whether islet regeneration could be achieved within the adult rat pancreas by gene therapy using UTMD.
The embryological development of the endocrine pancreas is associated with the activation of a number of genes encoding various transcription factors and other proteins. 12, 13 Recognizing that there may be important differences between neonatal endocrine development and islet regeneration in an adult animal with diabetes, we sought to evaluate whether the latter could be accomplished by gene therapy targeted to the pancreas by UTMD. We specifically constructed plasmids encoding cDNA for Ngn3, Pax4, Nkx2.2, Nkx6.1, MafA and NeuroD1, all under the control of the modified rat insulin promoter (RIP3.1). Microbubbles containing these genes were infused intravenously over a 10-min period while ultrasound was used to destroy the microbubbles within the pancreatic microcirculation. UTMD was performed 48 h after the induction of diabetes by intraperitoneal STZ (60 mg kg
À1
). Controls included UTMD with a marker gene (RIP3.1-DsRed), STZ only without gene therapy, as well as normal controls that did not receive STZ. Three different repetitions of the experiments were carried out, with euthanization at 10 days, 20 days and 30 days, to evaluate islet morphology and gene expression. Results of the 30-day experiment are shown in the figures. A long-term experiment was also performed using RIP3.1-NeuroD1, after this gene was shown to be optimal for islet regeneration in this model.
Results
Effects of endocrine proliferative genes on islet structure Figure 1 shows representative histological samples stained with FITC-labeled anti-insulin antibodies (green) and CY5-labeled anti-glucagon antibodies (red). These sections were obtained from a group of rats killed 30 days after UTMD. Normal islets contain a central core of b-cells (green) surrounded by a smaller number of a-cells (red) at the periphery of the islet. After STZ, the normal islet architecture is virtually abolished, with isolated b-cells or small clusters of b-cells occasionally remaining. Gene therapy with Ngn3, Pax4, Nkx2.2, Nkx6.1 and MafA resulted in the regeneration of islets, but with an abnormal islet architecture, in which a-cells were predominant. In contrast, gene therapy with NeuroD1 resulted in the regeneration of islets with relatively normal morphology. Interestingly, there were a few cells that costained with anti-insulin and antiglucagon in the NeuroD1 group (Figure 2 ), but not in normal islets. This finding has been previously reported to be a marker for endocrine proliferation. 13 Confocal microscopy also showed colocalization of anti-insulin and anti-Ki67, indicating b-cell proliferation (data not shown). Compared with normal and STZ-treated control groups, Ki67-positive cells were statistically and significantly more numerous (10±2% of insulin-positive cells, Po0.0001) in the NeuroD1 group than in controls (only rare Ki67-positive cells). As NeuroD1 was under the control of the RIP3.1 promoter, we hypothesized that the observed islet regeneration was due to the replication of b-cells that survived STZ. This was supported by three At day 3, all STZ-treated rats had markedly elevated blood glucose and decreased insulin and C-peptide relative to normal controls (Po0.0001). However, by day 30, only the NeuroD1-treated rats had restoration of blood glucose, insulin and C-peptide to normal or nearly normal levels.
Regeneration of pancreatic islets by gene therapy S Chen et al observations. First, there was no evidence of islet regeneration when RIP3.1-NeuroD1 was delivered by UTMD 7 days after STZ, a time point in which no residual b-cells were identified in STZ controls. Second, none of the islets induced by RIP3.1-NeuroD1 expressed CK19, indicating that the new islets were not derived from ductal cells. Third, the colocalization of Ki67 and insulin suggested b-cell proliferation.
Effects of endocrine proliferative genes on blood glucose, insulin and C-peptide Figure 1 also shows plots of blood glucose (top right), insulin (middle right) and C-peptide (bottom right) levels at baseline, 3 days after STZ and 30 days after STZ. The blood glucose level increased dramatically by day 3 in all rats treated with STZ (approximately 400 mg per 100 ml), and remained elevated at day 30, except in NeuroD1-treated rats. At day 30, the blood glucose level was 101 ± 11 mg per 100 ml in NeuroD1-treated rats, which was statistically and significantly lower than that of all other STZ-treated groups (Po0.0001), but not of normal controls. In the shorter-term experiments, blood glucose level was also normal at days 10 and 20 in NeuroD1-treated rats (data not shown). Insulin and C-peptide levels were markedly depressed at day 3 in all STZ-treated rats. By day 30, insulin and C-peptide levels were nearly normal in NeuroD1-treated rats, being statistically and significantly higher than that at day 3 or higher than that of all other STZ-treated groups (Po0.0001).
Effects of endocrine proliferative genes on islet count and b-cell mass Islet morphometry 30 days after UTMD is shown in Figure 3 . The top panels are representative low-power sections stained with hematoxylin (blue) and anti-insulin (brown) from normal controls (left), Ngn3-treated rats (middle) and NeuroD1-treated rats (right). The number of islets in the various treatment groups is shown in the bottom left graph of Figure 3 . In normal controls, there were 61±6 islets per slide, compared with only 3±2 after STZ treatment alone. NeuroD1 resulted in 37 ± 4 islets per slide, a number that was statistically and significantly higher than that of all other groups, except of normal controls (Po0.0001). b-cell mass is shown in the bottom right graph of Figure 3 . b-cell mass was 1.49 ± 0.17% in normal controls, and was dramatically reduced in STZ-treated controls (0.04 ± 0.01%) and DsRed controls (0.05 ± 0.01%). In the groups treated with PAX4, Nkx2.2, Nkx6.1, Ngn3 and Mafa, b-cell mass was similar (0.20 ± 0.04%). However, in rats treated with NeuroD1 gene therapy, b-cell mass was restored to roughly half of that of normal controls (0.76 ± 0.07%). b-cell mass was statistically and significantly higher for NeuroD1-treated rats than for all other genes and controls (Po0.0001), but was less than that of normal controls (P ¼ 0.0006).
Duration of islet regeneration after RIP3.1-NeuroD1 gene therapy Regeneration of pancreatic islets by gene therapy S Chen et al normal controls, STZ-treated controls and the NeuroD1 group at two time points, 2 and 4 weeks after UTMD. No NeuroD1 signal is present in the islets of normal or STZ-treated rats. In rats treated with NeuroD1 gene therapy, NeuroD1 is present at 2 weeks, but not 4 weeks after UTMD. This is consistent with our previous report that plasmid DNA expression by UTMD peaks 4-7 days after treatment, and is virtually gone by 4 weeks. Thus, transient gene expression by UTMD triggers islet regeneration that persists after clearance of the delivered gene and the expressed protein.
To determine the duration of islet regeneration and blood glucose control after UTMD, a group of six different rats were treated with NeuroD1 gene therapy 2 days after STZ and killed 90 days later. The results of this experiment are shown in Figure 5 . All six rats were profoundly hyperglycemic at baseline (2 days after STZ). At days 20 and 30, all six rats had normal blood glucose levels (graph, left panel). However, by day 90, four of the six rats had return of severe hyperglycemia, whereas two rats remained normoglycemic. Confocal microscopy showed substantial loss of b-cells in the islet center of hyperglycemia rats (top right), compared with normoglycemic rats (bottom right), which had preserved islet architecture.
Prolongation of islet viability by c-Jun N-terminal kinase inhibition
We hypothesized that this late loss of islets was due to apoptosis. Therefore, the experiment was repeated by pretreatment with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor that has been shown to block JNKmediated apoptosis in islets. 14 Figure 6 shows the results of Tunel staining in normal controls (n ¼ 3), in STZtreated diabetic rats (n ¼ 3) and in STZ rats treated with NeuroD1 gene therapy with (n ¼ 6) and without SP600125 (n ¼ 6). Apoptosis (green signal) was abolished in the NeuroD1 UTMD group that received pretreatment with SP600125. Figure 7 shows islet morphometry and blood glucose measurements 90 days after NeuroD1 gene therapy with and without SP600125. The left panels show representative islets in rats that did not receive SP600125 (top) compared with those that were retreated with SP600125 (bottom). Large well-formed islets were seen in the SP600125 group, compared with small clusters of b-cells present in controls (No SP600125). b-cell mass was 0.61 ± 0.07% in the SP600125 group compared with 0.37±0.07% in controls (Po0.0001; top right graph). Blood glucose levels at 90 days are shown in the bottom right graph of Figure 7 . The blood sugar level was significantly lower in the NeuroD1-treated SP600125 group than in the NeuroD1 group that did not receive SP600125 (Po0.05), but was higher than that of normal controls (Po0.05). This was because of the return of hyperglycemia in two of six rats treated with SP600125.
Discussion
To our knowledge, this is the first study to show in vivo regeneration of pancreatic islets with recovery from diabetes without using a viral vector. Specifically, NeuroD1 was targeted to the pancreas of STZ-treated rats with subsequent regeneration of nearly normalappearing islets and restoration of normal blood levels of glucose, insulin and C-peptide at 30 days. The peak expression of reporter genes delivered as plasmids by UTMD was seen in 4 days, with rapid degradation thereafter. 8 Thus, transient gene expression by this method is capable of inducing islet regeneration while theoretically minimizing the risk of insertional mutagenesis that might be associated with prolonged Regeneration of pancreatic islets by gene therapy S Chen et al expression of exogenous gene therapy. By pretreating the rats with SP600125 that has been shown to block b-cell apoptosis, we were able to extend the duration of islet regeneration and normoglycemia to 90 days in the rat model of STZ-induced diabetes.
NeuroD1 is a basic helix-loop-helix transcription factor that is found in the pancreas, intestine and central nervous system. 15 NeuroD1 is present at pancreatic bud development and remains detectable in all mature islet cell types. In NeuroD1 knockout mice, all endocrine cell types develop, but there is a decreased number of islets and increased b-cell apoptosis. 16 It is thought that NeuroD1 is not essential for early differentiation, but has an important role in later-stage differentiation and maintenance of b-cells, and in cell fate determination. 17, 18 This view of the role of NeuroD1 in endocrine development, although based primarily on transgenic mouse studies, is consistent with the observed finding of islet regeneration in adult rats in this study.
Other transcription factors, specifically Ngn3, Pax4, Nkx2.2, Nkx6.1 and MafA, also resulted in islet regeneration, but the islets were comprised predominantly of a-cells, and blood glucose, insulin and C-peptide levels were not normalized. Interestingly, transgenic mice expressing Ngn3 under regulation of a Pdx1 promoter show mostly glucagon-positive cells, 19 similar to our findings after in vivo delivery of Ngn3. When Ngn3 is overexpressed in developing chicken gut, it also predominantly produces a-cells. 20 It seems likely that the role of these transcription factors when delivered exogenously to adult animals with diabetes may differ from their role in embryological development. It is also possible that various combinations of transcription factor genes or other genes implicated in pancreatic development or cell cycling would result in even more robust islet regeneration than that observed in this study. For example, Chen et al. 10 showed that insulin production by acinar cells could be induced in STZ-treated rats by the combination of Figure 4 Immunostaining for the presence of NeuroD1 protein in normal controls (top panels), STZ-treated rats (second panels), 2 weeks after NeuroD1 gene therapy (third panels) and 4 weeks after NeuroD1 gene therapy (bottom panels). Left panels are stained with anti-insulin FITC (green); center panels with anti-NeuroD1 CY5 (red); and right panels are confocal. Detectable levels of NeuroD1 are seen in b-cells 2 weeks, but not 4 weeks after ultrasound-targeted microbubble destruction (UTMD).
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betacellulin and Pdx1 plasmids delivered in vivo with restoration of normal blood glucose and insulin levels for up to 15 days. More recently, Zhou, et al. 11 reported that the combination of Ngn3, MafA and Pdx1, delivered by direct injection of adenovirus into the pancreas of immune-deficient mice, resulted in reprogramming of exocrine cells to a b-cell phenotype. These new b-cells were isolated into single cells or small clusters of only a few cells, rather than aggregating into islets. Blood glucose, insulin and C-peptide levels were improved, but not restored to normal levels. When single-transcription factors were delivered, new b-cells were not seen in significant numbers. This study differs in two potentially important aspects. First, we used a nonviral gene delivery method that, unlike direct injection, targets the entire pancreas. Second, we used the RIP3.1 promoter to selectively target gene expression to the endocrine pancreas. The more commonly used cytomegalovirus promoter is more efficient in exocrine than in endocrine pancreas. 21 Similarly, adenovirus is more robust in exocrine than in endocrine pancreas. 22 Islet regeneration has been achieved in STZ-mediated diabetes by using adenovirus to deliver various genes to the liver, with a resultant restoration of the normal blood glucose Regeneration of pancreatic islets by gene therapy S Chen et al level. 4, 5 However, adenovirus is not likely to be used in humans because of safety considerations. Although the liver is a suitable organ for islet regeneration and islet transplantation, our technique uses ultrasound-mediated microbubble destruction to deliver plasmid cDNA to the whole pancreas with relatively potent organ specificity. This offers a theoretical advantage for islet regeneration and maintenance, as the pancreas is the normal physiological milieu for islets. As in our previous studies of gene delivery by UTMD, [8] [9] [10] we did not find any evidence of pancreatic damage by UTMD, either by serum amylase or lipase, or by histology.
We did not perform complex studies of cell lineage. However, several observations suggest that the regenerated islets observed after RIP3.1-NeuroD1 result from replication of scattered b-cells that survived STZ. Immunofluorescent staining with CK19, a ductal cell marker, did not show any significant uptake in the regenerated islets (data not shown). Islet regeneration was only seen to occur when gene delivery was administered immediately after STZ treatment or within 48 h after treatment. When the experiments were repeated with gene delivery 7 days after STZ, a time period in which there were no detectable insulin-staining cells in STZ control rats, islet regeneration was not seen and there was progression of severe hyperglycemia and weight loss. Colocalization of Ki67 and insulin was present in the regenerated islets, suggesting b-cell proliferation. We used a modification of the rat insulin-I promoter, which is strongly b-cell specific, particularly under conditions of hyperglycemia, 8, 9 and would not be expected to have substantial activity in exocrine pancreas. These considerations are consistent with the prevailing view that b-cell replication is the predominant mechanism for increasing b-cell mass. 13, 23, 24 The concept of using gene therapy to promote islet regeneration in diabetic humans is plausible. Meier et al. showed that 88% of autopsy specimens from adult humans with long-standing type 1 diabetes had substantial numbers of b-cells, as well as b-cell apoptosis and T-lymphyocyte infiltration. 25 Thus, existing b-cells are a potential target for regenerative gene therapy with NeuroD1, alone or in combination with other transcription factors. However, any strategy to regenerate islets will also have to account for potential destruction of new islets by apoptosis, inflammation or autoimmunity. 2 We used SP600125 to reduce b-cell apoptosis and extend the duration of efficacy after NeuroD1 gene therapy. It should be possible to combine regenerative genes with genes or drugs that inhibit apoptosis, 14, [26] [27] [28] and/or the autoimmune response. With regard to the latter, recent evidence suggests that tacrolimus and sirolimus might have direct toxic effects on b-cells. 29 Thus, the optimal immunosuppressive regimen for islet protection may not yet be established. Finally, there are important differences between rodent and human islet biology; 2 hence, these findings need to be confirmed in higher-order animals before human trials can be contemplated.
Materials and methods
Rat insulin promoters and plasmid constructs
Sprague-Dawley rat genomic DNA was extracted from rat peripheral blood with a QIAamp Blood kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. Rat insulin gene-I promoter fragments (À412 to +165) were amplified from Sprague-Dawley rat genomic DNA using PCR. The resulting DNA fragments were subcloned into the pDsRed1-1 reporter vector (Clonetech, Mountain view, CA, USA). hMafA . Blood glucose level is lower in NeuroD1-treated rats that received SP600125 compared with those that did not receive SP600125 (Po0.05), but is higher than that in normal controls (Po0.05).
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cDNA and hamster Nkx6.1 cDNA were donated or cordially gifted by the Olson lab (East Lansing, MI, USA) at Michigan State University and by the Newgard lab (Durham, NC, USA) at Duke University Medical Center. Rat Ngn3, NeuroD1, Pax4 and Nkx2.2 cDNAs were PCR products from Sprague-Dawley newborn rat pancreas cDNA pool that were reversed from their total RNA according to the manufacturer's instructions. Newborn rat pancreatic samples were flash frozen in liquid nitrogen and stored at À86 1C. The frozen samples were thawed in 1 ml of RNA-STAT solution and immediately homogenized using a polytron homogenizer at 10 000 r.p.m. for 30 s. Total RNA (30 ng) was reverse transcribed in 20 ml using a Sensiscript RT kit (Qiagen Inc.) with oligo(dT)16. The reaction mixture was incubated at 42 1C for 50 min, followed by a further incubation at 70 1C for 15 min. PCR was performed for all samples using a GeneAmp PCR System 9700 (PE ABI, Foster City, CA, USA) in 50 ml volume containing 2 ml of cDNA, 25 ml of HotStarTaq Master Mix (Qiagen Inc.) and 20 pmol of each primer. The corresponding PCR products were verified by agarose gel electrophoresis and purified by a QIAquick Gel Extraction kit (Qiagen Inc.). To confirm the sequences, PCR products were directly sequenced using a dRhodamine Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3100 Genomic Analyzer (Van Allen Way, Carlsbad, CA, USA). All transcriptional factor gene cDNAs were subcloned to RIP3.1 driving vector. Plasmid digestion, ligation, subclone, isolation and purification were performed by standard procedures, and once again sequenced to confirm that no artifactual mutations were present.
Animal protocols and UTMD
All animal studies were performed in accordance with the National Institute of Health (NIH) recommendations and after obtaining the approval of our local IACUC. The left abdomen and neck of male Sprague-Dawley rats (230-270 g) anesthetized with intraperitoneal ketamine (60 mg kg
À1
) and xylazine (5 mg kg À1 ) were shaved, and a polyethylene tube (PE 50, Becton Dickinson, Franklin Lakes, TN, USA) was inserted into the right internal jugular vein by cut-down.
A total of 45 rats received one of nine treatments: (1) no treatment (normal control rats, n ¼ 3); (2) treatment with STZ (60 mg kg À1 per intraperitoneal, Sigma, St Louis, MO, USA) alone without UTMD (n ¼ 3); (3) treatment with STZ and UTMD with DsRed (n ¼ 3); (4) with STZ and UTMD with ngn3 (n ¼ 6); (5) STZ and UTMD with NeuroD1 (n ¼ 6); (6) STZ and UTMD with Pax4 (n ¼ 6); (7) STZ and UTMD with Nkx2.2 (n ¼ 6); (8) STZ and UTMD with Nkx6.1 (n ¼ 6); (9) with STZ and UTMD with MafA (n ¼ 6). All genes were delivered as plasmid cDNA under the control of the RIP3.1 promoter. Blood glucose level was measured 12 h after STZ injection. Animals with a fasting blood glucose level over 250 mg per 100 ml were considered as successful diabetes type 1 models and subsequently underwent UTMD within 48 h of STZ treatment. Microbubble or control solutions (0.5 ml diluted with 0.5 ml phosphatebuffered solution (PBS)) were infused for over 10 min using a pump (Genie, Kent Scientific, Torrington, CT, USA). During the infusion, ultrasound was directed to the pancreas using a commercially available ultrasound transducer (S3, Sonos 5500, Philips Ultrasound, Bothell, WA, USA). The probe was clamped in place. Ultrasound was then applied in ultraharmonic mode (transmit 1.3 MHz/receive 3.6 MHz) at a mechanical index of 1.4. Four bursts of ultrasound were triggered to every fourth end-systole by electrocardiogram using a delay of 45-70 ms after the peak of the R wave. These settings have been shown to be optimal for plasmid delivery by UTMD using this instrument. 8 Bubble destruction was visually apparent in all rats. After UTMD, the jugular vein was tied off, the skin was closed and the animals were allowed to recover. Blood samples were drawn after an overnight 12-h fast at baseline, and at different days after treatment. This protocol was repeated three times with 135 rats killed at days 10 (n ¼ 45), 20 (n ¼ 45) and 30 (n ¼ 45) using an overdose of sodium pentobarbital (120 mg kg À1 ). Pancreas, liver, spleen and kidney were harvested for histological examination. Blood glucose level was measured using a blood glucose test strip (Precision, Abbott, Abbott Park, IL, USA); blood insulin and C-peptide levels were measured using an RIA kit (Linco Research, Radioimmunoassay, Billerica, MA, USA).
For the 90-day experiments, only RIP3.1-NeuroD1 was administered by UTMD (n ¼ 6), along with three normal controls, in which STZ was not given, and three STZ controls. This experiment was then repeated with pretreatment of rats with SP600125 (n ¼ 6) before UTMD with RIP3.1-NeuroD1 and without such pretreatment (n ¼ 6).
Manufacture of plasmid-containing lipid-stabilized microbubbles
Lipid-stabilized microbubbles were prepared as previously described in our laboratory. Briefly, a stock solution is prepared containing 270 mg of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (Sigma), 30 mg of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (Sigma) and 1 g of glucose. These ingredients are dissolved in a boiling water bath for 20-30 min, with pipetting out of contents up and down until no visible particles remain. This stock solution is stored at 4 1C. Plasmid-containing microbubbles are prepared by mixing 2 mg of dried plasmid with 50 ml of lipefectamine 2000 (Invitrogen, Carlsbad, CA, USA) and incubating at room temperature for 15 min. This liposome or plasmid DNA mixture is added to 250 ml of lipid stock solution, 50 ml of pure glycerol and 5 ml of 10% albumin solution, mixed well with a pipette, and then placed in ice. Aliquots of 0.5 ml of this phospholipid-plasmid solution were placed in 1.5 ml clear vials; the air in the headspace of the vials is replaced with perfluoropropane gas (Air Products and Chemicals Inc., Allentown, PA, USA). Each vial was incubated at 4 1C for 30 min and then mechanically shaken for 30 s by a dental amalgamator (VialmixTM, Bristol-Myers Squibb Medical Imaging, N. Billerica, MA, USA). The lipid-stabilized microbubbles appear as a milky white suspension floating on the top of a layer of liquid containing unattached plasmid DNA. The subnatant was discarded and the microbubbles were washed three times with PBS to remove unattached plasmid DNA. The mean diameter and concentration of the microbubbles in the upper layer were measured by a particle counter (Beckman Coulter, Inc., Brea, CA, USA; Multisizer III). 
Immunohistochemistry
Cryostat sections 5-8 mm in thickness were fixed in 4% paraformaldehyde for 15 min at 4 1C and quenched for 5 min with10 mM glycine in PBS. Sections were then rinsed in PBS three times, and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Sections were blocked with 10% goat serum at 37 1C for 1 hr and washed with PBS three times. The primary antibody (mouse anti-insulin antibody, 1:500 dilution (Sigma); rabbit anti-glucagon, 1:500; rabbit anti-somatostatin, 1:500; rabbit anti-pancreatic polypeptide, 1:500; rabbit anti-NeuroD1, 1:500; rabbit anti-Ki-67, rabbit anti-BrDu, 1:500; mouse anti-ck19, 1:2000 dilution (Chemicon, Temecula, CA)) was added and incubated for 2 hrs at room temperture. After washing with PBS three times for 5 min, the secondary antibody (Sigma; anti-mouse IgG conjugated with FITC; anti-rabbit lgG conjugated with Cy5,1:500 dilution in block solution) was added and incubated for 1 hr at room temperature. Sections were rinsed with PBS for 10 min, five times, and then mounted.
Tunel staining
Tunel staining for detection and quantification of apoptosis in rat pancreas slides was performed using a commercially available kit (Roche Diagnostics, Indianapolis, IN, USA) according to a standard protocol. DNA strand breaks at the single-cell level were labeled with fluorescein and imaged by fluorescence microscopy.
b-cell mass calculation b-cell mass was evaluated by the method of Terauchi et al. 30 Sections of rat pancreas were immunostained with monoclonal mouse anti-insulin (1:500 dilution) and a second antibody, peroxidase-conjugated goat anti-mouse IgG (1:500 dilution), and developed in liquid DAB. Images from six consecutive pancreas sections were captured on a monitor screen of a digital imaging system (Olympus BX60, Nikon digital camera DXM1200C and NIS-Elements F2.30, Miami, FL, USA). The total areas of islet b-cells and whole pancreas were measured using NIH ImageJ software (NIH, Bethesda, MD, USA). b-cell mass was calculated as the ratio of b-cells to whole pancreas for six consecutive pancreatic slides from each rat.
Data analysis
Data were analyzed with Statview software (SAS, Cary, NC, USA). The results are expressed as mean±1s.d. Differences were analyzed by repeated measures ANOVA with Fisher's post hoc test and considered significant at Po0.05.
